Literature DB >> 27490052

Interface Fluid Syndrome After Laser In Situ Keratomileusis (LASIK) Because of Fuchs Endothelial Dystrophy Reversed by Descemet Membrane Endothelial Keratoplasty (DMEK).

Salvatore Luceri1, Zainab Baksoellah, Abbas Ilyas, Lamis Baydoun, Gerrit R J Melles.   

Abstract

PURPOSE: To describe a case that developed "interface fluid syndrome" after previous laser in situ keratomileusis (LASIK) because of Fuchs endothelial dystrophy (FED), which was reversed by Descemet membrane endothelial keratoplasty (DMEK).
METHODS: A 58-year-old male patient presented with bilateral visual impairment owing to FED and visually significant cataract. Cataract surgery was carried out in both eyes followed by DMEK in his left eye.
RESULTS: After cataract surgery, visual acuity did not improve sufficiently because corneal thickness increased and a fine cleft with interface fluid developed between the LASIK-flap and the residual stromal bed. After uneventful DMEK in his left eye, the fluid resolved within a week and visual acuity improved rapidly.
CONCLUSIONS: This case demonstrates that "interface fluid syndrome" after LASIK caused by concomitant endothelial dysfunction may be reversed by DMEK allowing fast visual recovery.

Entities:  

Mesh:

Year:  2016        PMID: 27490052     DOI: 10.1097/ICO.0000000000000971

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  2 in total

1.  DMEK for the treatment of interface fluid syndrome secondary to failed DSAEK graft: A case report and review of the literature.

Authors:  Nuno Moura-Coelho; Elena Arrondo; Mario Renato Papa-Vettorazzi; João Paulo Cunha; José Luis Güell
Journal:  Am J Ophthalmol Case Rep       Date:  2022-07-10

2.  Reversal of laser in situ keratomileusis interface fluid after Descemet stripping automated endothelial keratoplasty for pseudophakic bullous keratopathy.

Authors:  Arjun Srirampur; Anupama Kalwad; Tarannum Mansoori; Satish Agraharam
Journal:  Indian J Ophthalmol       Date:  2019-10       Impact factor: 1.848

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.